ScaleReady's G-Rex Grant Program Enhances Cell Therapy
ScaleReady has made significant efforts to support advancements in cell and gene-modified cell therapy, evident through their recent allocation of G-Rex Grants totaling $475,000 to remarkable investigators at the Baylor College of Medicine's Center for Cell and Gene Therapy. This program is part of their broader strategy to enhance research and development within this vital medical field.
Focused Research by Leading Baylor Investigators
Among the recipients is Dr. Ann Leen, who has been recognized with a $275,000 grant. Dr. Leen's research, focusing on tumor-associated neoantigen T cell therapies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), showcases her dedication since 2002 at Baylor. Her extensive experience, which includes over 100 publications and 14 patents related to G-Rex technology, positions her as a prominent figure in cell therapy advancements.
3D Tumor Spheroid Models
Another grant of $100,000 was awarded to Dr. Katie McKenna. Dr. McKenna aims to pioneer a new G-Rex-based approach for culturing three-dimensional solid tumor spheroids. These models are intended to provide more accurate representations of the tumor microenvironment, offering more reliable data compared to traditional murine studies. By developing organoid models specifically for pancreatic, breast, and lung cancer, her work is set to push boundaries in cancer research.
Innovative Gene Editing Platforms
Dr. Dimitrios Laurin Wagner and Dr. Marie Pouzolles also received a $100,000 grant for their innovative pursuits in gene editing. Their project will utilize a non-viral CRISPR-Cas-based method to enhance the manufacture of gene-edited T cells. With backgrounds in pivotal research roles, they are committed to shifting genome editing into clinical applications, signaling a transformative step toward enhanced anti-cancer therapies.
Impact of the G-Rex Grant Program
John Wilson, CEO of Wilson Wolf Manufacturing and co-inventor of the G-Rex technology, expressed his enthusiasm for the grant program, emphasizing the collaborative spirit at Baylor's Center for Cell and Gene Therapy. With G-Rex being a gold standard in T cell therapy manufacturing, the contributions from these accomplished investigators are set to foster further advancements in the field.
The G-Rex Grant Program emerges from ScaleReady's overall commitment, reflecting a robust $20 million initiative aimed at propelling cell therapy manufacturing and development. Each grant, with a maximum amount of up to $300,000, enables researchers to gain access to essential resources and experienced partners in the industry, enhancing their capacity to conduct groundbreaking work.
Collaboration and Support
Grant recipients benefit not only from financial support but also from being part of ScaleReady's extensive network. This network provides unparalleled resources and insights into good manufacturing practices (cGMP), quality assurance, and business operations. Such supportive frameworks are crucial to streamlining and accelerating the path to commercialization in cell therapies.
About ScaleReady and Its Partners
ScaleReady is dedicated to revolutionizing the landscape of cell and gene-modified therapies by offering the highly versatile G-Rex manufacturing platform. This platform is gaining traction across more than 800 organizations, supporting approximately 50% of ongoing CGT clinical trials and contributing to several commercially approved CGT drugs.
The overarching mission of ScaleReady, alongside its partners like Wilson Wolf Manufacturing and Bio-Techne Corporation, is to deliver superior services while ensuring substantial savings in time and resources for entities involved in CGT commercialization.
Frequently Asked Questions
What is the G-Rex Grant Program?
The G-Rex Grant Program is an initiative by ScaleReady to support research in cell and gene-modified therapies by providing financial assistance and collaboration opportunities to leading investigators.
Who received grants from ScaleReady?
Notable recipients include Dr. Ann Leen, Dr. Katie McKenna, and Dr. Dimitrios Laurin Wagner, each focusing on pioneering research in cancer therapies.
How much funding can researchers receive?
Researchers can receive individual grant awards up to $300,000 as part of the G-Rex Grant Program.
What is the goal of the G-Rex technology?
The G-Rex technology aims to enhance the scalability, flexibility, and affordability of cell and gene-modified therapy manufacturing, thus revolutionizing drug product development.
How does ScaleReady support its partners?
ScaleReady provides its partners access to extensive resources, including expertise in cGMP manufacturing and regulatory affairs, ensuring streamlined processes in CGT development.
